Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Swedbank AB

Swedbank AB raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 722,243 shares of the medical equipment provider's stock after acquiring an additional 125,843 shares during the quarter. Swedbank AB owned approximately 1.04% of Lantheus worth $79,266,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Penserra Capital Management LLC bought a new position in shares of Lantheus during the 3rd quarter worth $1,331,000. Cerity Partners LLC grew its position in shares of Lantheus by 19.8% during the 3rd quarter. Cerity Partners LLC now owns 11,897 shares of the medical equipment provider's stock worth $1,306,000 after buying an additional 1,966 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Lantheus in the third quarter valued at about $25,955,000. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Lantheus during the third quarter valued at about $8,372,000. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of Lantheus in the 3rd quarter valued at about $435,000. Institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price on the stock. Truist Financial reiterated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities dropped their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Price Performance

LNTH traded up $0.44 during trading on Monday, reaching $90.96. 1,343,879 shares of the company's stock were exchanged, compared to its average volume of 1,022,109. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a market capitalization of $6.32 billion, a P/E ratio of 15.13 and a beta of 0.51. The company's fifty day simple moving average is $103.13 and its 200-day simple moving average is $96.93.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.